Ehsan Shahverdi
Background: Systemic and intrathecal adenosine reduce chronic neuropathic and nociceptive pain; however, the effect of adenosine epidural injection in the treatment of neuropathic cancer- related pains remains unclear. Objectives: The objective of this study was to evaluate the efficacy of a single epidural administration of adenosine in alleviating chronic neuropathic pain in patients with primitive neuroectodermal tumors. Methods: In this single-blind randomized clinical trial with the unique ID of IRCT2017031428878N1, 88 patients with chronic neuropathic pain were divided into two equivalent groups. Two groups were treated with a single dose epidural administration of ropivacaine, 0.75 mL/kg from 0.2% solution (both groups), plus adenosine, 50 mcgr/kg (adenosine group), or normal saline (control group). Patients were evaluated on the days 1, 2, 3, 5, 7, 10, and 14 after injection. Results: Both groups showed a reduction in pain severity according to verbal rating scale (VRS) (3 ± 0.09-1 ± 0.05 in adenosine, 4 ± 0.08-1 ± 0.00 in the control group) and visual analogue scale (VAS) (7 ± 0.25-1 ± 0.12 in adenosine, 8 ± 0.22-1 ± 0.06 in the controlgroup); however, this reduction was significantly higher in the controlgroup (P< 0.0005). The intensity of neuropathicpain decreased in both groups according to Douleur Neuropathique 4 questions(DN4) scores(from 5±0.23-1±0.04 in adenosine group, and from 5.5 ± 0.24-1 ± 0.00 in the control group) without a significant difference between the groups (P = 0.19). Adenosine group had less nausea and vomiting (P < 0.0005).There was no significant difference in patient satisfaction levels between adenosine and control groups (P = 0.09). Conclusions: Administration of bolus epidural adenosine is not effective in reducing neuropathic pain in patients with primitive neuroectodermal tumors.
PDFShare this article
Archives of Surgical Oncology received 37 citations as per Google Scholar report
